Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3767-3771

  Perrotta, Cristiana ^a,b   Falcone, Sestina ^c,d   Capobianco, Annalisa ^b   Camporeale, Annalisa ^b   Sciorati, Clara ^b   De Palma, Clara ^a,b   Pisconti, Addolorata ^b   Rovere Querini, Patrizia ^b   Bellone, Matteo ^b   Manfredi, Angelo A ^b   Clementi, Emilio ^b,c,d,e  

^a UNIVERSITY OF CALABRIA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (2 AMINOETHYL) N (2 AMMONIOETHYL)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; ANTINEOPLASTIC AGENT; CASPASE 9; CYCLIC GMP; NITRIC OXIDE; NITRIC OXIDE DONOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CASPASE 9; CASPASES; CYCLIC GMP; DENDRITIC CELLS; ENZYME ACTIVATION; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE DONORS; TRIAZENES;

EID: 2542562703     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0668     Document Type: Article

References (22)

1. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
2. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-6.
3. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164:1269-6.
4. Esche C, Lokshin A, Shurin GV, et al. Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999;66:336-44.
5. Pirtskhalaishvili G, Shurin GV, Gambotto A, et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 2000;165:1956-64.
6. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer (Phila) 2000;89:2646-54.
7. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000;60:6391-5.
8. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001;61:7530-5.
9. Lundqvist A, Choudhury A, Nagata T, et al. Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther 2002;13:1541-9.
10. Tourkova IL, Yurkovetsky ZR, Gambotto A, et al. Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15R α and Bcl-2. J Leukoc Biol 2002;72:1037-45.
11. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Investig 2003;112:109-17.
12. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003;63:6378-86.
13. Liu L, Stamler JS. NO: an inhibitor of cell death. Cell Death Differ 1999;6:937-42.
14. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol 2001;167:3773-84.
15. Sciorati C, Rovere P, Ferrarini M, Heltai S, Manfredi AA, Clementi E. Autocrine nitric oxide modulates CD95-induced apoptosis in γδ T lymphocytes. J Biol Chem 1997;272:23211-5.
16. Shimamura H, Cumberland R, Hiroishi K, Watkins SC, Lotze MT, Baar J. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J Immunother 2002;25:226-34.
17. Paolucci C, Rovere P, De Nadai C, Manfredi AA, Clementi E. Nitric oxide inhibits the tumor necrosis factor α-regulated endocytosis of human dendritic cells in a cyclic GMP-dependent way. J Biol Chem 2000;275:19638-44.
18. Paolucci C, Burastero SE, Rovere-Querini P, et al. Synergism of nitric oxide and maturation signals on human dendritic cells occurs through a cyclic GMP-dependent pathway. J Leukoc Biol 2003;73:253-62.
19. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003;63:3688-94.
20. Scaduto RC Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999;76:469-77.
21. Vanderheyde N, Aksoy E, Amraoui Z, Vandenabeele P, Goldman M, Willems F. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J Immunol 2001;167:3565-9.
22. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann N Y Acad Sci 2002;962:360-71.